Passage Bio
PASG
50 hedge funds and large institutions have $33.1M invested in Passage Bio in 2023 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 14 increasing their positions, 10 reducing their positions, and 7 closing their positions.
40% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 10
29% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 7
13% more capital inflows, than outflows
Capital inflows: $3.2M | Capital outflows: $2.82M
4% more funds holding
Funds holding: 48 → 50 (+2)
0.66% more ownership
Funds ownership: 59.09% → 59.76% (+0.66%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Tang Capital Management
San Diego,
California
|
+$1.38M |
| 2 |
Millennium Management
New York
|
+$464K |
| 3 |
Erste Asset Management
Vienna,
Austria
|
+$414K |
| 4 |
Pale Fire Capital SE
Prague,
Czech Republic
|
+$333K |
| 5 |
Renaissance Technologies
New York
|
+$158K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
-$1.35M |
| 2 |
Frazier Life Sciences Management
Palo Alto,
California
|
-$1.16M |
| 3 |
Morgan Stanley
New York
|
-$113K |
| 4 |
Weiss Multi-Strategy Advisers
New York
|
-$86.1K |
| 5 |
Squarepoint
New York
|
-$48.7K |
PASG Hedge Fund Activity: Q4 2023 in Review
50 of the 6,876 institutional investors tracked by Wall St. Rank reported a position in Passage Bio (PASG) for Q4 2023, worth a combined $33.1M — up 55% from $21.3M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new PASG positions and 7 closed out — a net gain of 2 holders — while 14 added to existing stakes and 10 trimmed.
The largest buyer was Tang Capital Management, adding an estimated $1.38M. The largest seller was BML Capital Management, exiting entirely with an estimated $1.35M sold.
- 50 institutional investors held Passage Bio (PASG) as of Q4 2023, up from 48 in Q3 2023.
- Funds reported $33.1M of Passage Bio stock for Q4 2023, up 55% quarter-over-quarter.
- 9 funds opened new Passage Bio positions in Q4 2023 and 7 closed out, a net change of +2 holders.
- The largest Passage Bio buyer in Q4 2023 was Tang Capital Management, an estimated $1.38M added.
- The largest Passage Bio seller in Q4 2023 was BML Capital Management, an estimated $1.35M sold.
Based on aggregated 13F filings for Q4 2023.